Denali Therapeutics (DNLI) Debt Ratio (2022)

Denali Therapeutics' (DNLI) quarterly Debt Ratio came in at 0.0 in Q4 2022, up 155.64% on a QoQ basis from 0.0 in Q3 2022.

Denali Therapeutics (DNLI) Debt Ratio (2022) Analysis & Trends

Denali Therapeutics (DNLI) has 1 years of Debt Ratio data on file, last reported at 0.0 in Q4 2022.

On a quarterly basis, Debt Ratio changed N/A year-over-year to 0.0 in Q4 2022; TTM through Dec 2022 was 0.0, a N/A change from a year earlier, with the FY2022 full-year figure at 0.0, changed N/A from the prior year.
Debt Ratio for Q4 2022 stood at 0.0, up from 0.0 in the prior quarter.
Over the last five years, Debt Ratio for DNLI reached as high as 0.0 in Q4 2022 and fell as low as 0.0 in Q3 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Denali Therapeutics	4.37 Bn	4.37 Bn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2022	0.00
Sep 30, 2022	0.00
Mar 31, 2022	0.00